Development of Focal segmental glomerulosclerosis 4- years following direct-acting antiviral therapy for hepatitis C virus infection: Case report | ||||
| Medical Journal of Viral Hepatitis | ||||
| Article 1, Volume 6.1, Issue 1, December 2021, Page 1-3 PDF (264.61 K) | ||||
| Document Type: Research articles | ||||
| DOI: 10.21608/mjvh.2021.211703 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Abdelmoneim Elhadidy  1; Rania Maher2; Ahmed Ehab2
| ||||
| 1Gastroetetro- and Hepatology dept., Damietta fever hospital, Egypt | ||||
| 2Hepatology and Gastroentrology Unit, Damietta Cardiology and Gastroenterology Center, Damietta, Egypt. | ||||
| Abstract | ||||
| It is well celebrated that, eradication of HCV RNA from serum is commonly accompanied by clinical improvement of glomerular abnormalities. Sofosbuvir (SOF) is the only commonly used direct-acting antiviral therapies (DAAs) that is primarily cleared by kidney. The effect of sustained virologic response (SVR) on renal function is well-established in the setting of interferon (IFN) based regimens. Patients who achieved SVR with IFN regimens have a decreased incidence of chronic kidney disease and endstage renal disease. However this effect following DAAs therapy is scarce. There is no clinically relevant change in renal function among the majority of HCV-infected patients following completion of DAA-based treatments. During follow up of patients with SVR following DAAs therapy, we observed one patient has 4 years SVR post DAAs (Sofosbuvir plus dacklatavir) who developed resistant edema and ascites with massive proteinuria following treatment with DAAs therapies and whose kidney biopsies demonstrated focal segmental glomerulosclerosis (FSGS) hilar type and interstitial fibrosis and tubular atrophy. | ||||
| Keywords | ||||
| Focal segmental glomerulosclerosis; hepatitis C virus infection; direct-acting antiviral therapies; sustained virologic response | ||||
|
Statistics Article View: 157 PDF Download: 242 |
||||
